A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months
Latest Information Update: 03 Aug 2026
At a glance
- Drugs Levonorgestrel (Primary) ; Medroxyprogesterone (Primary)
- Indications Endometrial hyperplasia
- Focus Therapeutic Use
- Acronyms SUNFLOWER
- Sponsors Bayer
Most Recent Events
- 30 Jul 2026 Status changed from discontinued to withdrawn prior to enrolment.
- 14 Jul 2026 Status changed from recruiting to discontinued.
- 23 Jun 2026 Planned End Date changed from 1 Oct 2027 to 1 Nov 2027.